France Is First EU Country to Give Abivax Go-ahead to Test ABX464 in Ulcerative Colitis

France Is First EU Country to Give Abivax Go-ahead to Test ABX464 in Ulcerative Colitis
France has become the first European country to give Abivax a green light to start clinical trials of ABX464 as a treatment for moderate-to-severe active ulcerative colitis. The therapy candidate is already being tested against HIV/AIDS. Belgium, Czech Republic, Germany, Hungary, Poland and Spain are expected to follow the French National Regulatory Authority in authorizing trials for ulcerative colitis. ABX464, which is in Phase 2 clinical trials for patients with HIV/AIDS, blocks the replication of the human immunodeficiency virus. It also has anti-inflammatory qualities that help treat HIV/AIDS a
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *